Updated:
Trinity Innovation Fund
Trinity Innovation Fund launched in 2018 as a Beijing-headquartered venture capital firm dedicated to biotechnology and innovative drug platforms.
Trinity Innovation Fund
Trinity Innovation Fund launched in 2018 as a Beijing-headquartered venture capital firm dedicated to biotechnology and innovative drug platforms. Its mandate is anchored by a tripartite model — scientists, professional managers, and investors collaborating inside each deal — which the firm calls "scientist, professional manager, investor trinity: let science serve health." The firm manages multiple venture capital funds and has invested in dozens of biotech companies. The firm operates across early-stage seed, start-up, expansion, and late-stage venture investments in biopharma. Its portfolio concentrates on drug modalities including siRNA, antibody-drug conjugates, and small-molecule therapeutics. Portfolio companies with confirmed activity include RiboBio (siRNA, collaborator with Boehringer Ingelheim), Argo Biopharmaceuticals (siRNA licensing deals with Novartis totaling up to $9.6 billion across two transactions), TransThera Sciences (oncology drug tinengotinib, listed on the Hong Kong Stock Exchange as 02617.HK in June 2025, with Chipscreen Biosciences and Akeso as collaboration partners), OrangeBio (bispecific ADC licensing to an undisclosed partner for $800 million), and Adcentrx Therapeutics (STEAP1-targeting ADC cleared for US clinical trials). The firm's geographic footprint spans domestic Chinese R&D and outward-facing global licensing to partners including Novartis, Bayer, and Boehringer Ingelheim. Trinity's portfolio has generated a sequence of high-value licensing transactions in the 2024–2026 window. In February 2025, portfolio company Puhe Biopharmaceuticals signed a global license agreement with Bayer for a Phase I PRMT5 inhibitor. In November 2024, OrangeBio completed an $800 million out-licensing deal for a Nectin4/TROP2 bispecific ADC. In 2026, Argo Biopharmaceuticals extended its Novartis relationship with a siRNA transaction valued at up to $5.2 billion. A single 2026 milestone reported by the firm aggregated $4.4 billion in disclosed nucleic-acid therapeutics deal value. Trinity Innovation Fund is structurally distinct from generalist China VC funds by functioning as a dedicated biopharma engine whose deal flow is co-architected by in-house scientific and drug-development operators rather than purely financial analysts. The firm's repeated appearances on licensing announcements alongside European and US pharmaceutical partners reflect a sourcing model that pairs domestic Chinese early-stage science with the regulatory and commercial channels of global pharma counterparties.
General information
Firm type
Private Equity
Year founded
2018
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Sector focus
Frequently asked questions
How does Trinity Innovation Fund source its investment opportunities?
Trinity operates a "scientist, professional manager, investor trinity" model. Its team members hold deep industry backgrounds spanning pharmaceutical R&D, business development, equity research, and corporate strategy — and these same people participate in evaluating and structuring investments. The firm's public deal flow shows heavy concentration in novel drug modalities emerging from Chinese academic and biotech ecosystems that subsequently secure licensing agreements with global pharmaceutical companies.
Does Trinity Innovation Fund participate in fund commitments or only direct deals?
Trinity manages multiple venture capital funds and invests directly into biotechnology companies. No publicly available information indicates that the firm acts as a limited partner in third-party funds or runs a fund-of-funds program. Its publicly visible activity is wholly comprised of direct equity investments and company-building.
Which therapeutic modalities and drug types does Trinity Innovation Fund focus on?
The firm concentrates on biotechnology and innovative drug platforms. Publicly identifiable portfolio holdings and licensing transactions span siRNA therapeutics, antibody-drug conjugates (including bispecific ADCs targeting Nectin4/TROP2 and STEAP1), small-molecule oncology drugs, and targeted radionuclide therapies. This pattern suggests a modality-agnostic approach within drug development, weighted toward nucleic acid therapeutics and next-generation biologics.
What is Trinity Innovation Fund's relationship to the companies it invests in?
Trinity Innovation Fund takes lead or significant minority positions and actively supports portfolio companies through development milestones and global licensing negotiations. The firm frequently announces that its investee companies — RiboBio, Argo Biopharmaceuticals, OrangeBio, and others — have entered clinical-stage collaborations or out-licensing agreements with multinational pharmaceutical companies, indicating a hands-on role in partnering strategy.
How does Trinity Innovation Fund generate liquidity for its investments?
Liquidity events appear concentrated in out-licensing transactions and, in at least one case, a public listing. Portfolio company TransThera Sciences completed its Hong Kong IPO in June 2025 (per the firm, June 2025). Additionally, multiple Trinity-backed biotechs have executed large-dollar licensing deals — a pattern consistent with a thesis that relies on pre-revenue asset sales to global pharma partners as the primary return mechanism.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: